Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY) | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1The Role of Early Biologic Therapy in Inflammatory Bowel DiseaseRCT · 2019 · 220 citations
2Study of tumor necrosis factor receptor in the inflammatory bowel diseaseOriginal Research · 2023 · 142 citations
3Can We Predict the Efficacy of Anti-TNF-α Agents?Prognostic Study · 2017 · 78 citations
4Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel DiseaseReview · 2014 · 108 citations
525 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the futureOriginal Research · 2021 · 152 citations
6Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobettersCost-Effectiveness Analysis · 2021 · 34 citations
7Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseRCT · 2021 · 245 citations
8Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 EraClinical Trial · 2022 · 29 citations
9Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease courseJournal of Crohn s and Colitis · 2026
10Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn’s diseaseJournal of Crohn s and Colitis · 2026

More from Journal of Crohn s and Colitis

More from University of California, San Diego